Anna Jonasova

List of Publications by Year
in descending order

66 papers	1,220 citations	471509 17 h-index	377865 34 g-index
67 all docs	67 docs citations	67 times ranked	1808 citing authors

#	Article	IF	Citations
1	Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. Cells, 2022, 11, 223.	4.1	5
2	Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes. Cancer Genomics and Proteomics, 2022, 19, 205-228.	2.0	4
3	RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia, 2022, 36, 1898-1906.	7.2	7
4	G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Blood Cancer Journal, 2022, 12, .	6.2	2
5	Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. Cancers, 2021, 13, 2161.	3.7	2
6	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	1.6	49
7	Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. Molecular Oncology, 2020, 14, 2403-2419.	4.6	7
8	Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution. Genes Chromosomes and Cancer, 2020, 59, 396-405.	2.8	1
9	Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome. Cells, 2020, 9, 794.	4.1	26
10	<scp>NQO</scp>1*2 polymorphism predicts overall survival in <scp>MDS</scp> patients. British Journal of Haematology, 2019, 184, 305-308.	2.5	2
11	MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia. Cancer Biomarkers, 2018, 22, 101-110.	1.7	19
12	High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype. Leukemia Research, 2018, 68, 85-89.	0.8	2
13	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	1.3	5
14	Lenalidomide treatment in lower risk myelodysplastic syndromesâ€"The experience of a Czech hematology center. (Positive effect of erythropoietin Â± prednisone addition to lenalidomide in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 21	0.8	
15	Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice. International Journal of Gerontology, 2018, 12, 27-31.	0.6	1
16	Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Cells, 2018, 7, 138.	4.1	14
17	Differential expression of homologous recombination <scp>DNA</scp> repair genes in the early and advanced stages of myelodysplastic syndrome. European Journal of Haematology, 2017, 99, 323-331.	2.2	7
18	Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. Oncotarget, 2017, 8, 111966-111978.	1.8	8

#	Article	IF	Citations
19	TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget, 2016, 7, 36266-36279.	1.8	47
20	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	1.6	190
21	Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine. OncoImmunology, 2016, 5, e1183860.	4.6	17
22	Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. International Journal of Hematology, 2016, 104, 566-573.	1.6	14
23	Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia. Leukemia Research, 2016, 43, 51-57.	0.8	8
24	Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. Leukemia Research, 2016, 42, 7-12.	0.8	27
25	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061.	1.6	0
26	Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome. Blood, 2016, 128, 4294-4294.	1.4	0
27	Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment. Cancer Genetics, 2015, 208, 156-161.	0.4	12
28	High level of fullâ€length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. European Journal of Haematology, 2015, 95, 27-34.	2.2	26
29	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. British Journal of Haematology, 2015, 168, 361-370.	2.5	59
30	Genomeâ€wide mi RNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. European Journal of Haematology, 2015, 95, 35-43.	2.2	18
31	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood, 2015, 126, 2880-2880.	1.4	1
32	Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness. Blood, 2015, 126, 4103-4103.	1.4	0
33	Altered Expression of the Repair Genes in CD34+ Cells May be Responsible for Formation and Accumulation of Mutations in MDS Patients. Blood, 2015, 126, 4119-4119.	1.4	0
34	Changes of Pro-Inflammatory Cytokines in Bone Marrow of MDS Patients in Response to Treatment with 5-Azacytidine. Blood, 2015, 126, 2895-2895.	1.4	0
35	Azacitidine Blocks GATA-1-Mediated Repression of the PU.1 Gene in Human Leukemic Cells. Blood, 2015, 126, 5220-5220.	1.4	0
36	Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome. General Physiology and Biophysics, 2015, 34, 399-406.	0.9	3

#	Article	IF	Citations
37	The translocation t(2;11)(p21;q23) without MLL gene rearrangementâ€"a possible marker of good prognosis in myelodysplastic syndrome patients. Hematological Oncology, 2014, 32, 82-86.	1.7	6
38	Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene, 2014, 33, 4735-4745.	5.9	26
39	Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. Leukemia Research, 2014, 38, 537-544.	0.8	24
40	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	1.4	11
41	Epigenetic Control of SPI1 Gene by CTCF and ISWI ATPase SMARCA5. PLoS ONE, 2014, 9, e87448.	2.5	25
42	Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes. Blood, 2014, 124, 859-859.	1.4	0
43	DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population. Journal of Hematology and Oncology, 2013, 6, 9.	17.0	14
44	Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamondâ€"Blackfan anemia. Annals of Hematology, 2013, 92, 11-18.	1.8	16
45	Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes and Cancer, 2013, 52, 619-635.	2.8	7
46	A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leukemia Research, 2013, 37, 1612-1615.	0.8	27
47	5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia, 2012, 26, 1804-1811.	7.2	44
48	Changes Associated With Lenalidomide Treatment in the Gene Expression Profiles of Patients With Del(5q). Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 375-383.	0.4	8
49	Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5qâ^' MDS (IPSS) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	5
50	Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies. Leukemia Research, 2012, 36, e43-e45.	0.8	5
51	Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites. Leukemia Research, 2012, 36, e125-e127.	0.8	1
52	Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1790-1790.	1.4	0
53	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. Blood, 2012, 120, 3163-3163.	1.4	0
54	Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome. Hemoglobin, 2011, 35, 217-227.	0.8	31

#	Article	IF	Citations
55	Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO Journal, 2011, 30, 4450-4464.	7.8	85
56	The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,. Blood, 2011, 118, 3825-3825.	1.4	1
57	Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine,. Blood, 2011, 118, 3791-3791.	1.4	0
58	Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice. Blood Cells, Molecules, and Diseases, 2010, 44, 257-261.	1.4	15
59	Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome. Experimental Hematology, 2009, 37, 386-394.	0.4	6
60	P064 Erythropoietin and iron overload as opposite regulators of hepcidin expression. Leukemia Research, 2009, 33, S96-S97.	0.8	0
61	P081 The questions on megakaryopoiesis in MDS patients with del(5q). Leukemia Research, 2009, 33, S105.	0.8	0
62	Nature of frequent deletions in CEBPA. Blood Cells, Molecules, and Diseases, 2009, 43, 260-263.	1.4	3
63	Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome.. Blood, 2009, 114, 2788-2788.	1.4	1
64	P102 Thrombocytopenia at diagnosis as an important independent negative prognostic marker for low risk MDS patients. Leukemia Research, 2007, 31, S95.	0.8	0
65	Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood, 2004, 104, 1855-1858.	1.4	80
66	Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology, 1998, 100, 304-309.	2.5	192